{
    "pmcid": "8828845",
    "qa_pairs": {
        "How does the tetravalent Nb1\u2013Nb2-Fc format improve the nanobody's properties?": [
            "By increasing neutralization potency and stability",
            "By reducing the molecular weight of the nanobody",
            "By enhancing the nanobody's ability to cross the blood-brain barrier",
            "By decreasing the immunogenicity of the nanobody"
        ],
        "What is the primary target of the biparatopic nanobody Nb1\u2013Nb2 developed in the study?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What is the significance of the biparatopic design of Nb1\u2013Nb2?": [
            "It enhances binding affinity and neutralization breadth by targeting distinct epitopes on the RBD.",
            "It reduces the size of the nanobody for easier delivery.",
            "It allows the nanobody to bind to multiple viruses simultaneously.",
            "It increases the production yield of the nanobody."
        ],
        "What mechanism do Nb1 and Nb2 use to block viral entry into host cells?": [
            "They compete with ACE2 for binding to the RBD.",
            "They degrade the viral RNA genome.",
            "They inhibit the viral protease enzyme.",
            "They disrupt the viral lipid envelope."
        ],
        "Which method was used to identify high-affinity nanobodies targeting the RBD of SARS-CoV-2?": [
            "Synthetic nanobody phage display library screening",
            "CRISPR-Cas9 gene editing",
            "In vivo immunization of camelids",
            "Yeast surface display"
        ]
    }
}